Liquid Biopsy-Guided Adjuvant Therapy in Bladder Cancer
News Context
At a glance
- Recent research indicates that adjuvant atezolizumab therapy considerably improves survival outcomes for patients diagnosed with muscle-invasive bladder cancer.
- The presence of ctDNA, even without visible signs of metastasis, suggests residual disease and a higher risk of recurrence.
- This details is based on research findings as of november 14, 2025, and is intended for informational purposes only.
Atezolizumab Shows Benefit in Muscle-Invasive Bladder Cancer with Circulating Tumor DNA
Research Highlight
Key Findings
Recent research indicates that adjuvant atezolizumab therapy considerably improves survival outcomes for patients diagnosed with muscle-invasive bladder cancer. This benefit was observed specifically in individuals who, despite showing no evidence of disease spread on radiographic imaging, were found to have detectable circulating tumor DNA (ctDNA) in their bloodstream.
The presence of ctDNA, even without visible signs of metastasis, suggests residual disease and a higher risk of recurrence. Atezolizumab, an immunotherapy drug, appears to effectively target and eliminate these remaining cancer cells in this patient population, leading to improved overall survival.